Considering our analysis, we proposed screening of HIE patients at three critical time points: (i) within the first 24 h of life using VEGF, GFAP, and IL-10; (ii) before completion of TH using tau, GFAP, and IL-10; and (iii) by 72 h after completion of TH with tau and GFAP (Figure 3C). The gene discussed is VEGFA; the disease is perinatal asphyxia.